Bleomycin (NSC-125066): phase I clinical study.
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use / Q000633:toxicity; D001774:Blood Chemical Analysis; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D012877:Skin Manifestations; D013280:Stomatitis / Q000139:chemically induced; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin